• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    23andMe Reports Second Quarter Fiscal 2024 Financial Results

    11/8/23 4:05:00 PM ET
    $GSK
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

    Recent Highlights

    Consumer

    • Increased kit and subscription pricing, seeing better than expected results, helping improve margin profile and highlighting increasing value of product to consumers.
    • Launched 23andMe+ Total Health - 23andMe's most advanced prevention-based health membership. It includes clinical grade exome sequencing, biannual blood biomarker testing and access to clinicians with unique training in genetics. Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
    • Continued to improve the value of our 23andMe+ Premium subscription - Launched two new digital health features. HealthTracksTM is a new behavior change digital health tool integrating lifestyle and genetics into a single model for the first time. Health Action PlanTM draws on personalized genetic reports, health history survey data, as well as blood and biomarker data to provide tailored, bite-sized health recommendations for subscribers to take action.
    • Launched new FDA-authorized pharmacogenetics report on Simvastatin, a commonly prescribed cholesterol-lowering drug in the statin class.
    • Received FDA clearance to report 41 additional genetic variants in the BRCA1 and BRCA2 genes.



    Therapeutics

    • Presented updated data for 23ME-00610 at the Society for Immunotherapy of Cancer (SITC) conference on November 3. The presented Phase 1 data shows compelling pharmacokinetics, tolerability and evidence of immune activation due to the inhibition of the CD200R1 pathway. Phase 2a enrollment is ongoing with initial efficacy and cohort data expected in 2024.  



    Research

    • Announced a new, non-exclusive data license with GSK plc (NYSE:GSK) which extends the previous collaboration and enables GSK to conduct drug target discovery and other research using the 23andMe database, the world's largest recontactable resource of genetic and phenotypic information from consented participants. Under an amendment to the collaboration agreement, 23andMe will receive a $20 million upfront payment for a one year, non-exclusive data license. The license will also include access to certain services such as further analyses of the 23andMe data not provided in the core data release.
    • New historical DNA analysis by researchers at 23andMe, Harvard University, and the Smithsonian Institution was featured on the cover of Science Magazine. The study revealed more about the enslaved and freed African Americans who labored at a Maryland iron furnace just after the founding of the United States. It leveraged 23andMe's large research database to find connections between these people and more than 40,000 of their living relatives.

    "The Company recently hit multiple meaningful milestones with the launch of our HealthTracks tool for our 23andMe+ subscribers, the addition of multiple new health-focused reports and the recent launch of Total Health. We are executing on our vision of helping our customers improve their health in a personalized and actionable way," said Anne Wojcicki, Co-Founder & CEO of 23andMe. "In Therapeutics, we recently presented encouraging Phase 1 data for 23ME-00610 at SITC, and are excited to be moving into the early efficacy portion of the development cycle. We continued to make progress on improving our margin profile and cash runway, and to position the business to thrive over both the medium and long term."

    Financial Results

    Total revenue for FY24 Q2 was $50 million, compared to $76 million for the same period in the prior year, representing a decrease of 34%. The decrease was primarily driven by lower Research Services revenue as the GSK collaboration exclusive discovery term concluded in July 2023, providing one month of collaboration revenue in the quarter while the prior year period included a full quarter of collaboration revenue, as well as lower revenue from non-recurring payments from other partners in the same period in the prior year. The decrease was also attributable to lower Consumer Services revenue as we focused on driving improved margins through higher average selling prices and marketing efficiency, reducing advertising spend and price discounting, resulting in lower volumes of personal genome service (PGS) kit sales and telehealth orders. This was partially offset by growth in our subscription services revenue.

    Revenue from Consumer Services, which includes PGS, telehealth and subscription services, represented approximately 97% of total revenue for the period. Research Services revenue accounted for approximately 3% of total revenue.

    Operating expenses for FY24 Q2 were $101 million, compared to $106 million for the same period in the prior year. The improvement in operating expenses was primarily due to reductions in marketing advertising spend aimed to boost margin and advertising efficiency as noted previously. The improvement also reflects lower personnel-related expenses following the reductions in force in the prior and current fiscal quarter along with the disposition of Lemonaid Health Limited in the UK in August 2023, partially offset by continued investment in Therapeutics portfolio advancement and one-time expenses related to the workforce reduction and UK disposition.

    Net loss for FY24 Q2 was $75 million, compared to a net loss of $66 million for the same period in the prior year.

    Adjusted EBITDA (as defined below) for FY24 Q2 was a loss of $45 million, compared to a loss of $30 million for the same period in the prior year. The increase in adjusted EBITDA deficit was primarily due to lower Research Services gross profit as the GSK collaboration exclusive discovery term concluded in July 2023 and increasing Therapeutics expenses, partially offset by reductions in marketing advertising spend, as noted above. Please refer to the tables below for a reconciliation of U.S. GAAP to Non-U.S. GAAP financial measures.

    Balance Sheet

    23andMe ended September 30, 2023 with cash and cash equivalents of $256 million, compared to $387 million as of March 31, 2023.

    FY2024 Financial Guidance

    The Company is partially adjusting its full year guidance following Q2 FY2024 results. Revenue guidance for FY2024, which will end on March 31, 2024, is adjusted to be in the range of $240 million to $250 million, with net loss reaffirmed to be in the range of $345 million to $325 million. Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.

    Within the existing lines of the PGS and telehealth Consumer businesses, the Company is prioritizing margin expansion and progressing toward cash flow profitability. These efforts include enhancements to existing services like the recently announced HealthTracks and Health Action Plan tools within 23andMe+ Premium, development of new services like the newly launched Total Health membership, and the reorganization of the Consumer & Research Services segment to streamline its expense profile, like the workforce reduction earlier in the year and the more recent disposition of the UK subsidiary in August.

    Similarly within Therapeutics, with the end of the exclusive discovery term under the GSK collaboration in July, the Company decided to narrow its discovery efforts to inflammation and immunology and development efforts in immuno-oncology to focus on areas that best align with its core strengths. The Company completed a workforce reduction in August to realign resources with the revamped structure and took the royalty option on three programs initiated together with GSK to reduce cash burn.

    We expect these decisions to yield meaningful economic benefit in future periods as we continue building on the personalized, comprehensive health insights provided by services within the Consumer segment, like the newly launched Total Health membership, and continue to expand upon and realize the value of the database's insights through licensing and other deals, like the recently announced extension of the GSK collaboration.

    Conference Call Webcast Information

    23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress. The webcast can be accessed at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address.

    About 23andMe

    23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.



    Additional Information

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, potential future collaborations, database growth and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

    Use of Non-GAAP Financial Measures

    To supplement the 23andMe's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (GAAP), this press release also includes references to Adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to: changes in fair value of warrant liabilities, litigation settlements, gains or losses on dispositions of subsidiaries, and transaction-related costs if applicable for the periods presented. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

    Adjusted EBITDA is a key measure used by 23andMe's management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe's annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe's core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe's business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe's management and board of directors.

    In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe's presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Adjusted EBITDA is our best proxy for cash burn.



    Contacts

    Investor Relations Contact: [email protected]

    Media Contact: [email protected]



           
    23andMe Holding Co.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (In thousands, except share and per share data)

    (Unaudited)
           
      Three Months Ended

    September 30,
      Six Months Ended

    September 30,
     
      2023  2022  2023  2022 
    Revenue $49,999  $75,659  $110,863  $140,172 
    Cost of revenue  28,270   37,386   58,453   76,409 
    Gross profit  21,729   38,273   52,410   63,763 
    Operating expenses:            
    Research and development  54,588   52,598   116,917   104,607 
    Sales and marketing  18,328   24,835   40,986   58,269 
    General and administrative  25,290   28,881   76,030   58,524 
    Restructuring and other charges  2,654   —   6,871   — 
    Total operating expenses  100,860   106,314   240,804   221,400 
    Loss from operations  (79,131)  (68,041)  (188,394)  (157,637)
    Other income (expense):            
    Interest income, net  3,752   1,392   8,059   1,637 
    Other income (expense), net  145   (687)  477   (1,122)
    Loss before income taxes  (75,234)  (67,336)  (179,858)  (157,122)
    Provision for (benefit from) income taxes  36   (1,271)  36   (1,525)
    Net loss  (75,270)  (66,065)  (179,894)  (155,597)
    Other comprehensive income, net of tax  954   829   620   1,453 
    Total comprehensive loss $(74,316) $(65,236) $(179,274) $(154,144)
    Net loss per share of Class A and Class B common stock attributable to common stockholders:            
    Basic and diluted $(0.16) $(0.15) $(0.38) $(0.35)
    Weighted-average shares used to compute net loss per share:            
    Basic and diluted  474,858,266   449,899,537   468,592,009   448,211,708 

      



           
    23andMe Holding Co.

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share amounts)
           
      September 30,  March 31, 
      2023  2023 
      (Unaudited)    
    ASSETS      
    Current assets:      
    Cash and cash equivalents $256,386  $386,849 
    Restricted cash  1,399   1,399 
    Accounts receivable, net  1,501   1,897 
    Inventories  14,979   10,247 
    Deferred cost of revenue  5,782   5,376 
    Prepaid expenses and other current assets  17,948   19,224 
    Total current assets  297,995   424,992 
    Property and equipment, net  32,805   38,608 
    Operating lease right-of-use assets  52,549   56,078 
    Restricted cash, noncurrent  6,974   6,974 
    Internal-use software, net  18,971   15,661 
    Intangible assets, net  37,835   45,520 
    Goodwill  351,744   351,744 
    Other assets  2,357   3,021 
    Total assets $801,230  $942,598 
    LIABILITIES AND STOCKHOLDERS' EQUITY      
    Current liabilities:      
    Accounts payable $8,546  $12,924 
    Accrued expenses and other current liabilities  44,686   66,430 
    Deferred revenue  40,283   62,521 
    Operating lease liabilities  8,086   7,541 
    Total current liabilities  101,601   149,416 
    Operating lease liabilities, noncurrent  72,963   77,763 
    Other liabilities  1,415   1,480 
    Total liabilities  175,979   228,659 
    Stockholders' equity      
    Preferred stock - par value $0.0001, 10,000,000 shares authorized as of September 30, 2023 and March 31, 2023; zero shares issued and outstanding as of September 30, 2023 and March 31, 2023  —   — 
    Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 311,339,539 and 293,020,474 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively; Class B shares, 350,000,000 shares authorized, 167,491,460 and 168,179,488 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively  48   46 
    Additional paid-in capital  2,311,481   2,220,897 
    Accumulated other comprehensive loss  —   (620)
    Accumulated deficit  (1,686,278)  (1,506,384)
    Total stockholders' equity  625,251   713,939 
    Total liabilities and stockholders' equity $801,230  $942,598 



        
    23andMe Holding Co.

    Condensed Consolidated Statements of Cash Flows

    (In thousands)

    (Unaudited)
        
      Six Months Ended

    September 30,
     
      2023  2022 
    Cash flows from operating activities:      
    Net loss $(179,894) $(155,597)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Depreciation and amortization  13,714   16,747 
    Amortization and impairment of internal-use software  2,514   2,078 
    Stock-based compensation expense  74,840   59,430 
    Loss (gain) on disposal of property and equipment  (5)  4 
    Loss on disposition of Lemonaid Health Limited  2,026   — 
    Other operating activities  (504)  — 
    Changes in operating assets and liabilities:      
    Accounts receivable, net  396   (49,502)
    Inventories  (4,733)  (3,017)
    Deferred cost of revenue  (406)  914 
    Prepaid expenses and other current assets  (2,433)  4,899 
    Operating right-of-use assets  3,529   3,689 
    Other assets  664   (834)
    Accounts payable  (3,951)  (26,968)
    Accrued expenses and other current liabilities  (5,674)  (10,367)
    Deferred revenue  (22,237)  18,984 
    Operating lease liabilities  (4,255)  (4,426)
    Other liabilities  (65)  (2,008)
    Net cash used in operating activities  (126,474)  (145,974)
    Cash flows from investing activities:      
    Purchases of property and equipment  (715)  (1,945)
    Proceeds from sale of property and equipment  5   2 
    Capitalized internal-use software costs  (4,758)  (3,008)
    Net cash used in investing activities  (5,468)  (4,951)
    Cash flows from financing activities:      
    Proceeds from exercise of stock options  473   3,944 
    Proceeds from issuance of common stock under employee stock purchase plan  1,411   3,238 
    Payments of deferred offering costs  (263)  — 
    Payments for taxes related to net share settlement of equity awards  (142)  — 
    Net cash provided by financing activities  1,479   7,182 
    Effect of exchange rates on cash and cash equivalents  —   1,452 
    Net decrease in cash, cash equivalents and restricted cash  (130,463)  (142,291)
    Cash, cash equivalents and restricted cash—beginning of period  395,222   561,755 
    Cash, cash equivalents and restricted cash—end of period $264,759  $419,464 
    Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:      
    Cash and cash equivalents $256,386  $410,891 
    Restricted cash, current  1,399   1,599 
    Restricted cash, noncurrent  6,974   6,974 
    Total cash, cash equivalents and restricted cash $264,759  $419,464 



           
    23andMe Holding Co.

    Total Company and Segment Information and Reconciliation of Non-GAAP Financial Measures

    (In thousands)

    (Unaudited)
           
    The Company's revenue and Adjusted EBITDA by segment and for the total Company is as follows:
           
      Three Months Ended

    September 30,
      Six Months Ended

    September 30,
     
      2023  2022  2023  2022 
    Segment Revenue: (1)            
    Consumer and Research Services $49,999  $75,659  $110,863  $140,172 
    Total revenue $49,999  $75,659  $110,863  $140,172 
    Segment Adjusted EBITDA:            
    Consumer and Research Services Adjusted EBITDA $(6,673) $2,324  $(12,275) $(14,673)
    Therapeutics Adjusted EBITDA  (26,224)  (18,663)  (57,363)  (37,128)
    Unallocated Corporate (2)  (12,156)  (13,316)  (25,215)  (27,568)
    Total Adjusted EBITDA $(45,053) $(29,655) $(94,853) $(79,369)
    Reconciliation of net loss to Adjusted EBITDA:            
    Net loss $(75,270) $(66,065) $(179,894) $(155,597)
    Adjustments:            
    Interest income, net  (3,752)  (1,392)  (8,059)  (1,637)
    Other (income) expense, net  (145)  687   (477)  1,122 
    Provision for (benefit from) income taxes  36   (1,271)  36   (1,525)
    Depreciation and amortization  4,474   5,152   8,951   10,256 
    Amortization of acquired intangible assets  3,638   4,267   7,277   8,582 
    Stock-based compensation expense  23,741   28,967   74,840   59,430 
    Loss on disposition of Lemonaid Health Limited and transaction-related costs  2,127   —   2,375   — 
    Litigation settlement cost  98   —   98   — 
    Total Adjusted EBITDA $(45,053) $(29,655) $(94,853) $(79,369)
                     
    (1) There was no Therapeutics revenue for the three or six months ended September 30, 2023 and 2022.
    (2) Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.



        
    23andMe Holding Co.

    Reconciliation of GAAP Net Loss Outlook to Non-GAAP Adjusted EBITDA Outlook

    (in thousands)

    (Unaudited)
        
      Outlook for the Year Ending

    March 31, 2024
     
      as of November 8, 2023 
      Low  High 
    Reconciliation of estimated net loss to adjusted EBITDA:      
    GAAP Net Loss outlook $(345,000) $(325,000)
    Adjustments:      
    Estimated interest (income) expense, net  (12,174)  (12,174)
    Estimated other (income) expenses, net  (441)  (441)
    Estimated depreciation and amortization  18,369   18,369 
    Estimated amortization of acquired intangible assets  11,449   11,449 
    Estimated stock-based compensation expense  145,324   145,324 
    Estimated loss on disposition of Lemonaid Health Limited and transaction-related costs  2,375   2,375 
    Estimated litigation settlement cost  98   98 
    Non-GAAP adjusted EBITDA outlook $(180,000) $(160,000)



    Primary Logo

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK
    $ME

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    GSK plc
    $GSK
    5/30/2024$47.00Neutral
    Goldman
    GSK plc
    $GSK
    3/4/2024Neutral → Buy
    Guggenheim
    More analyst ratings

    $GSK
    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlaxoSmithKline downgraded by Deutsche Bank

      Deutsche Bank downgraded GlaxoSmithKline from Buy to Hold

      11/15/24 7:46:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kvarda Matthew

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:38:00 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Walper Thomas B.

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:35:46 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

      4 - 23andMe Holding Co. (0001804591) (Issuer)

      2/21/25 5:05:56 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

      Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old in the US2 GSK plc (LSE/NYSE:GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccines including GSK's AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease. This includes people with conditions like COPD, asthma, diabetes, heart disease and those in residential care3. This expands on ACIP's previous vote in June 2024 to recommend RSV vaccines fo

      4/16/25 5:36:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $ME
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/9/25 10:05:59 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 1:49:29 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 11:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $ME
    Leadership Updates

    Live Leadership Updates

    See more

    $GSK
    $ME
    Financials

    Live finance-specific insights

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

      SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

      11/12/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

      11/7/24 5:54:12 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

      11/7/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:48:20 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:20:24 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 23andMe Holding Co.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      11/13/24 6:00:29 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care